breast cancer | Research | Treatment | 10 pages | source: Cancer Medicine | Added Aug 22, 2021
Does lumpectomy followed by radiation improve survival outcomes in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes?
This study evaluated the survival outcomes after lumpectomy followed by radiation versus mastectomy alone in patients with early-stage HER2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC) with low or high tumor-infiltrating lymphocytes (TILs). The data showed that lumpectomy followed by radiation improves survival in patients with high TILs.
breast cancer | Research | Treatment | 10 pages | source: The New England Journal of Medicine | Added Aug 08, 2021
Evaluating olaparib for patients with BRCA1/2-positive breast cancer
This study looked at the use of olaparib (Lynparza) treatment for patients with high risk, BRCA1/2-positive, HER2-negative breast cancer (BC). The authors found that in patients with BRCA1/2-positive BC, olaparib after local treatment improved the outcomes of these patients.
rheumatoid arthritis | Research | 10 pages | source: Arthritis Research & Therapy | Added Jul 31, 2021
Can unacceptable pain be predicted in patients with early rheumatoid arthritis based on inflammation?
This study investigated the duration, level, and predictors of unacceptable pain during the early stages of rheumatoid arthritis (RA), with and without low inflammation. The authors concluded that over a 5-year period, more than one-third of patients studied had unacceptable pain that was linked to lower swollen joints.
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Jul 25, 2021
Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?
This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the 12-month visit with a TT switch within 6 months.
breast cancer | Research | 10 pages | source: Frontiers in oncology | Added Jul 23, 2021
Mental effects and depression induced by taxane-based chemotherapy in breast cancer survivors
This study aimed to investigate depression and cognitive (thinking and reasoning) functions after taxane-based chemotherapy in patients with breast cancer.
This study concluded taxane-based chemotherapy commonly leads to cognitive impairment in these patients, but some functions improve or remain stable after stopping treatment.
breast cancer | Research | Lifestyle | 10 pages | source: Scientific reports | Added Jul 21, 2021
Does exercise increase recovery in patients undergoing surgery for breast cancer?
This study was carried out to examine the impact of physical activity (PA) on the recovery of patients having surgery for breast cancer (BC). The authors found that PA reduces the risk of patients developing chronic pain and women who had higher levels of PA recovered better than sedentary women.
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Jul 11, 2021
Predicting the effectiveness of certolizumab pegol in rheumatoid arthritis by serum tumor necrosis factor alpha levels after 24 hours.
This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after the first dose.
rheumatoid arthritis | Research | 10 pages | source: European review for medical and pharmacological sciences | Added Jun 30, 2021
Do biological DMARDs affect fracture risk in patients with rheumatoid arthritis?
This study analyzed the effect of using biological disease-modifying anti-rheumatic drugs (bDMARDs) on fracture risk in patients with rheumatoid arthritis (RA). The data suggest no evidence that the use of bDMARDs impacts fracture risk in these patients.
rheumatoid arthritis | Research | 10 pages | source: The Journal of Rheumatology | Added Jun 13, 2021
Can COVID-19 vaccines be used in patients with autoimmune rheumatic diseases?
This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs.
breast cancer | Research | 10 pages | source: The Oncologist | Added Jun 13, 2021
Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?
This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients.